Christie Woodard, a 53-year-old resident of Easton, Maryland, has embarked on an extraordinary journey to maintain her normal weight after bariatric surgery and GLP-1 drugs. Her story highlights the complex relationship between weight management, medication, and personal health. Christie's experience is both inspiring and controversial, as she navigates the fine line between maintaining her weight and the potential risks associated with GLP-1 drugs.
Christie's weight struggles began in her 30s, when she battled obesity, eventually reaching 260 pounds. She turned to running half-marathons, but her weight made it a challenging endeavor. After gastric bypass surgery, she successfully halved her weight and set an ambitious goal: to complete half-marathons in all 50 states. Her weight remained stable for four years, but last year, she began to regain weight, despite her strict diet and exercise routine.
Her bariatric surgeon, Dr. Betsy Dovec, prescribed a low dose of the drug Zepbound, even though Christie's body mass index didn't technically classify her as overweight. Dr. Dovec explains that she prescribes medications for all types of people, but clarifies that she doesn't give the drugs for purely aesthetic reasons. GLP-1 drugs are meant to treat metabolic diseases like diabetes and obesity, but as they become more available, some people without excess weight seek them to slim down.
The controversy arises from the use of these obesity medicines for people with normal or mildly excess weight. Dr. Dovec argues that classifying this use as purely 'cosmetic' is a misunderstanding of the various circumstances patients face. The drugs treat more than just weight; they address metabolic diseases like diabetes or high blood pressure. Some doctors prescribe them off-label to manage alcohol use disorder, and obesity is a chronic disease, so multiple strategies may be needed to manage it.
However, Dr. Jennifer Manne-Goehler, an obesity specialist, is concerned that people will access these drugs and medicate themselves to meet a thinner ideal. This comes with risks, particularly the loss of muscle and potential for yo-yo dieting effects. Additionally, there are risks for people with disordered eating, as patients are not evaluated for these disorders when prescribed GLP-1 drugs.
Christie Woodard is no stranger to these controversies and the judgment around weight and weight management. Initially, she felt ashamed to admit she needed GLP-1s, especially after bariatric surgery. However, she came to understand that surgery alone didn't eliminate the disease of obesity, and she successfully advocated for GLP-1 coverage in her employer's health insurance plan. Her new perspective has helped her feel in control of her weight, making her happier and more effective at everything she does.
Christie's story is a powerful reminder of the complex relationship between weight management, medication, and personal health. It invites discussion about the appropriate use of GLP-1 drugs and the need for a nuanced understanding of the various circumstances patients face.
